New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:08 EDTLLYEli Lilly's Cyramza for liver cancer did not meet Phase III primary endpoint
Eli Lilly announced that the Phase III REACH trial of Cyramza in patients with hepatocellular carcinoma or liver cancer, did not meet its primary endpoint; overall survival favored the Cyramza arm but was not statistically significant. There were meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression. The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma after being treated with sorafenib in the first-line setting. No Phase III study of liver cancer has been able to demonstrate improved survival in the second-line setting. Lilly plans to present data from the REACH trial at a scientific meeting later this year.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
12:16 EDTLLYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
April 15, 2015
07:41 EDTLLYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 10, 2015
11:03 EDTLLYEli Lilly granted orphan status for anal cancer treatment
Subscribe for More Information
April 9, 2015
09:25 EDTLLYPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2015
07:14 EDTLLYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
07:14 EDTLLYBiodel GEM device demonstrates 'superior' usability
Biodel (BIOD) announced results from a formative human factors study of its Glucagon Emergency Management, or GEM, device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits; Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit. Furthermore, while training and previous experience increased the success rate with the Eli Lilly and Novo Nordisk glucagon kits, it did not further impact the already high success rate with the GEM device when compared to non-experienced, untrained participants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use